arrow_back Civic Audit
Share share

Biomedical Research Support: New Drugs and Therapies for Citizens

This act aims to accelerate the development of new drugs and therapies, especially in areas of unmet medical needs. Through the BioBonds program, companies and universities conducting clinical trials will be able to obtain funding, which may lead to the faster availability of innovative treatments for citizens.
Key points
A new BioBonds program will provide loans for clinical trials of drugs and medical devices intended to address unmet medical needs.
The U.S. government will guarantee up to 90% of the principal repayment of BioBonds, encouraging investors to fund innovative research.
The goal is to accelerate access to new, breakthrough therapies for patients who currently lack effective treatment options.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 118_HR_7539
Sponsor: Rep. Fitzpatrick, Brian K. [R-PA-1]
Process start date: 2024-03-05
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

LOANS for Biomedical Research Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_7539.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-03-05.

What are the main provisions?

Key points include:

  • A new BioBonds program will provide loans for clinical trials of drugs and medical devices intended to address unmet medical needs.
  • The U.S. government will guarantee up to 90% of the principal repayment of BioBonds, encouraging investors to fund innovative research.
  • The goal is to accelerate access to new, breakthrough therapies for patients who currently lack effective treatment options.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Fitzpatrick, Brian K. [R-PA-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

What is the impact of this bill?

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health Public Investments Economy